Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 153

1.

Non-tuberculous mycobacterial pulmonary disease.

Cowman S, van Ingen J, Griffith DE, Loebinger MR.

Eur Respir J. 2019 Jul 11;54(1). pii: 1900250. doi: 10.1183/13993003.00250-2019. Print 2019 Jul.

PMID:
31221809
2.

Comparative risks of chronic inhaled corticosteroids and macrolides for bronchiectasis.

Henkle E, Curtis JR, Chen L, Chan B, Aksamit TR, Daley CL, Griffith DE, Winthrop KL.

Eur Respir J. 2019 Jul 18;54(1). pii: 1801896. doi: 10.1183/13993003.01896-2018. Print 2019 Jul.

PMID:
31000676
3.

The Clinical Features of Bronchiectasis Associated with Alpha-1 Antitrypsin Deficiency, Common Variable Immunodeficiency and Primary Ciliary Dyskinesia--Results from the U.S. Bronchiectasis Research Registry.

Eden E, Choate R, Barker A, Addrizzo-Harris D, Aksamit TR, Daley CL, Daniels MLA, DiMango A, Fennelly K, Griffith DE, Johnson MM, Knowles MR, Metersky ML, Noone PG, O'Donnell AE, Olivier KN, Salathe MA, Schmid A, Thomashow B, Tino G, Turino GM, Winthrop KL.

Chronic Obstr Pulm Dis. 2019 Apr 9;6(2):145-153. doi: 10.15326/jcopdf.6.2.2018.0156. Epub 2019 Apr 9.

4.

Microbiome Diversity in Sputum of Nontuberculous Mycobacteria Infected Women with a History of Breast Cancer.

Philley JV, Kannan A, Olusola P, McGaha P, Singh KP, Samten B, Griffith DE, Dasgupta S.

Cell Physiol Biochem. 2019;52(2):263-279. doi: 10.33594/000000020. Epub 2019 Feb 28.

5.

Mycobacterium abscessus and antibiotic resistance: Same as it ever was.

Griffith DE.

Clin Infect Dis. 2019 Jan 26. doi: 10.1093/cid/ciz071. [Epub ahead of print] No abstract available.

PMID:
30689764
6.

Medical Management of Pulmonary Nontuberculous Mycobacterial Disease.

Philley JV, Griffith DE.

Thorac Surg Clin. 2019 Feb;29(1):65-76. doi: 10.1016/j.thorsurg.2018.09.001. Review.

PMID:
30454923
7.

Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT). A Prospective, Open-Label, Randomized Study.

Griffith DE, Eagle G, Thomson R, Aksamit TR, Hasegawa N, Morimoto K, Addrizzo-Harris DJ, O'Donnell AE, Marras TK, Flume PA, Loebinger MR, Morgan L, Codecasa LR, Hill AT, Ruoss SJ, Yim JJ, Ringshausen FC, Field SK, Philley JV, Wallace RJ Jr, van Ingen J, Coulter C, Nezamis J, Winthrop KL; CONVERT Study Group.

Am J Respir Crit Care Med. 2018 Dec 15;198(12):1559-1569. doi: 10.1164/rccm.201807-1318OC.

PMID:
30216086
8.

Mycobacterium avium Complex and Bronchiectasis. There's Something Happening Here . . .

Griffith DE, Aksamit TR.

Am J Respir Crit Care Med. 2018 Nov 15;198(10):1252-1253. doi: 10.1164/rccm.201807-1243ED. No abstract available.

PMID:
30092144
9.

Treatment of Mycobacterium avium Complex (MAC).

Griffith DE.

Semin Respir Crit Care Med. 2018 Jun;39(3):351-361. doi: 10.1055/s-0038-1660472. Epub 2018 Aug 2. Review.

PMID:
30071550
10.

Sputum Detection of Predisposing Genetic Mutations in Women with Pulmonary Nontuberculous Mycobacterial Disease.

Philley JV, Hertweck KL, Kannan A, Brown-Elliott BA, Wallace RJ Jr, Kurdowska A, Ndetan H, Singh KP, Miller EJ, Griffith DE, Dasgupta S.

Sci Rep. 2018 Jul 27;8(1):11336. doi: 10.1038/s41598-018-29471-x.

11.

US Patient-Centered Research Priorities and Roadmap for Bronchiectasis.

Henkle E, Aksamit TR, Daley CL, Griffith DE, O'Donnell AE, Quittner AL, Malanga E, Prieto D, Leitman A, Winthrop KL.

Chest. 2018 Nov;154(5):1016-1023. doi: 10.1016/j.chest.2018.06.032. Epub 2018 Jul 5.

PMID:
29981718
12.

Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement.

van Ingen J, Aksamit T, Andrejak C, Böttger EC, Cambau E, Daley CL, Griffith DE, Guglielmetti L, Holland SM, Huitt GA, Koh WJ, Lange C, Leitman P, Marras TK, Morimoto K, Olivier KN, Santin M, Stout JE, Thomson R, Tortoli E, Wallace RJ Jr, Winthrop KL, Wagner D; for NTM-NET.

Eur Respir J. 2018 Mar 22;51(3). pii: 1800170. doi: 10.1183/13993003.00170-2018. Print 2018 Mar. No abstract available.

13.

Mycobacterium abscessus, a taxonomic puzzle.

Tortoli E, Kohl TA, Brown-Elliott BA, Trovato A, Cardoso-Leão S, Garcia MJ, Vasireddy S, Turenne CY, Griffith DE, Philley JV, Niemann S, Wallace RJ, Cirillo DM.

Int J Syst Evol Microbiol. 2018 Jan;68(1):467-469. doi: 10.1099/ijsem.0.002457. Epub 2017 Nov 15. No abstract available.

PMID:
29139343
14.

Frequency of untreated hypogammaglobulinemia in bronchiectasis.

Ruffner MA, Aksamit TR, Thomashow B, Choate R, DiMango A, Turino GM, O'Donnell AE, Johnson MM, Olivier KN, Fennelly K, Daley CL, Winthrop KL, Metersky ML, Salathe MA, Knowles MR, Daniels MLA, Noone PG, Tino G, Griffith DE, Sullivan KE.

Ann Allergy Asthma Immunol. 2017 Jul;119(1):83-85. doi: 10.1016/j.anai.2017.04.020. Epub 2017 May 20. No abstract available.

15.

Pharmacotherapy for Non-Cystic Fibrosis Bronchiectasis: Results From an NTM Info & Research Patient Survey and the Bronchiectasis and NTM Research Registry.

Henkle E, Aksamit TR, Barker AF, Curtis JR, Daley CL, Anne Daniels ML, DiMango A, Eden E, Fennelly K, Griffith DE, Johnson M, Knowles MR, Leitman A, Leitman P, Malanga E, Metersky ML, Noone PG, O'Donnell AE, Olivier KN, Prieto D, Salathe M, Thomashow B, Tino G, Turino G, Wisclenny S, Winthrop KL.

Chest. 2017 Dec;152(6):1120-1127. doi: 10.1016/j.chest.2017.04.167. Epub 2017 May 5.

16.

Therapy of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis.

Seaworth BJ, Griffith DE.

Microbiol Spectr. 2017 Mar;5(2). doi: 10.1128/microbiolspec.TNMI7-0042-2017. Review.

PMID:
28361737
17.

The new "Hesitation Blues": initiating Mycobacterium avium complex lung disease therapy.

Griffith DE, Philley JV.

Eur Respir J. 2017 Mar 8;49(3). pii: 1700110. doi: 10.1183/13993003.00110-2017. Print 2017 Mar. No abstract available.

18.

Poor adherence to management guidelines in nontuberculous mycobacterial pulmonary diseases.

van Ingen J, Wagner D, Gallagher J, Morimoto K, Lange C, Haworth CS, Floto RA, Adjemian J, Prevots DR, Griffith DE; NTM-NET.

Eur Respir J. 2017 Feb 15;49(2). pii: 1601855. doi: 10.1183/13993003.01855-2016. Print 2017 Feb. No abstract available.

19.

Exosome secretome and mediated signaling in breast cancer patients with nontuberculous mycobacterial disease.

Philley JV, Kannan A, Griffith DE, Devine MS, Benwill JL, Wallace RJ Jr, Brown-Elliott BA, Thakkar F, Taskar V, Fox JG, Alqaid A, Bains H, Gupta S, Dasgupta S.

Oncotarget. 2017 Mar 14;8(11):18070-18081. doi: 10.18632/oncotarget.14964.

20.

Understanding nontuberculous mycobacterial lung disease: it's been a long time coming.

Griffith DE, Aksamit TR.

F1000Res. 2016 Nov 30;5:2797. eCollection 2016. Review.

21.

Nontuberculous Mycobacterial Disease Therapy: Take It to the Limit One More Time.

Griffith DE, Aksamit TR.

Chest. 2016 Dec;150(6):1177-1178. doi: 10.1016/j.chest.2016.07.015. No abstract available.

PMID:
27938739
22.

Emergence of mmpT5 Variants during Bedaquiline Treatment of Mycobacterium intracellulare Lung Disease.

Alexander DC, Vasireddy R, Vasireddy S, Philley JV, Brown-Elliott BA, Perry BJ, Griffith DE, Benwill JL, Cameron AD, Wallace RJ Jr.

J Clin Microbiol. 2017 Feb;55(2):574-584. doi: 10.1128/JCM.02087-16. Epub 2016 Dec 7.

23.

In Vitro Susceptibility Testing of Bedaquiline against Mycobacterium avium Complex.

Brown-Elliott BA, Philley JV, Griffith DE, Thakkar F, Wallace RJ Jr.

Antimicrob Agents Chemother. 2017 Jan 24;61(2). pii: e01798-16. doi: 10.1128/AAC.01798-16. Print 2017 Feb.

24.

Macrolide-Resistant Mycobacterium avium Complex: "I Feel Like I've Been Here Before".

Griffith DE.

Ann Am Thorac Soc. 2016 Nov;13(11):1881-1882. No abstract available.

PMID:
27831800
25.

Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease.

Olivier KN, Griffith DE, Eagle G, McGinnis JP 2nd, Micioni L, Liu K, Daley CL, Winthrop KL, Ruoss S, Addrizzo-Harris DJ, Flume PA, Dorgan D, Salathe M, Brown-Elliott BA, Gupta R, Wallace RJ Jr.

Am J Respir Crit Care Med. 2017 Mar 15;195(6):814-823. doi: 10.1164/rccm.201604-0700OC.

26.

Emended description of Mycobacterium abscessus, Mycobacterium abscessus subsp. abscessus and Mycobacteriumabscessus subsp. bolletii and designation of Mycobacteriumabscessus subsp. massiliense comb. nov.

Tortoli E, Kohl TA, Brown-Elliott BA, Trovato A, Leão SC, Garcia MJ, Vasireddy S, Turenne CY, Griffith DE, Philley JV, Baldan R, Campana S, Cariani L, Colombo C, Taccetti G, Teri A, Niemann S, Wallace RJ Jr, Cirillo DM.

Int J Syst Evol Microbiol. 2016 Nov;66(11):4471-4479. doi: 10.1099/ijsem.0.001376. Epub 2016 Aug 4.

PMID:
27499141
27.

When is a non-tuberculous mycobacterial infection a pulmonary disease?

Griffith DE, Lange C.

Int J Tuberc Lung Dis. 2016 Jul;20(7):855-6. doi: 10.5588/ijtld.16.0243. No abstract available.

PMID:
27287633
28.

Reply: Cure Not Possible, by Definition.

Griffith DE, Adjemian J, Brown-Elliott BA, Prevots DR, Philley JV, Olivier KN, Wallace RJ Jr.

Am J Respir Crit Care Med. 2015 Nov 15;192(10):1256-7. doi: 10.1164/rccm.201508-1515LE. No abstract available.

29.

Postcesarean section wound infection caused by Mycobacterium massiliense.

Wu TS, Yang CH, Brown-Elliott BA, Chao AS, Leu HS, Wu TL, Lin CS, Griffith DE, Chiu CH.

J Microbiol Immunol Infect. 2016 Dec;49(6):955-961. doi: 10.1016/j.jmii.2015.06.010. Epub 2015 Aug 14.

30.

Nontuberculous Mycobacterial Disease Research. An End to the Beginning.

Griffith DE.

Am J Respir Crit Care Med. 2015 Sep 1;192(5):535-7. doi: 10.1164/rccm.201506-1090ED. No abstract available.

PMID:
26325154
31.

Semiquantitative Culture Analysis during Therapy for Mycobacterium avium Complex Lung Disease.

Griffith DE, Adjemian J, Brown-Elliott BA, Philley JV, Prevots DR, Gaston C, Olivier KN, Wallace RJ Jr.

Am J Respir Crit Care Med. 2015 Sep 15;192(6):754-60. doi: 10.1164/rccm.201503-0444OC.

32.

Hit the Road, MAC, and Don't You Come Back No More.

Griffith DE, Brown-Elliott BA, Wallace RJ Jr.

Am J Respir Crit Care Med. 2015 Jun 1;191(11):1222-4. doi: 10.1164/rccm.201504-0774ED. No abstract available.

PMID:
26029835
33.

Impulse Oscillometry and Bronchiectasis. We Still Haven't Found What We're Looking For?

Philley JV, Griffith DE.

Ann Am Thorac Soc. 2015 May;12(5):621-2. doi: 10.1513/AnnalsATS.201502-100ED. No abstract available.

PMID:
25965535
34.

Treatment of slowly growing mycobacteria.

Philley JV, Griffith DE.

Clin Chest Med. 2015 Mar;36(1):79-90. doi: 10.1016/j.ccm.2014.10.005. Epub 2014 Nov 6. Review.

PMID:
25676521
35.

Preliminary Results of Bedaquiline as Salvage Therapy for Patients With Nontuberculous Mycobacterial Lung Disease.

Philley JV, Wallace RJ Jr, Benwill JL, Taskar V, Brown-Elliott BA, Thakkar F, Aksamit TR, Griffith DE.

Chest. 2015 Aug;148(2):499-506. doi: 10.1378/chest.14-2764.

36.

Mycobacterium abscessus. "Pleased to meet you, hope you guess my name...".

Griffith DE, Brown-Elliott BA, Benwill JL, Wallace RJ Jr.

Ann Am Thorac Soc. 2015 Mar;12(3):436-9. doi: 10.1513/AnnalsATS.201501-015OI. Review.

PMID:
25643064
37.

The tolerability of linezolid in the treatment of nontuberculous mycobacterial disease.

Winthrop KL, Ku JH, Marras TK, Griffith DE, Daley CL, Olivier KN, Aksamit TR, Varley CD, Mackey K, Prevots DR.

Eur Respir J. 2015 Apr;45(4):1177-9. doi: 10.1183/09031936.00169114. Epub 2015 Jan 22. No abstract available.

38.

Mycobacterium abscessus subsp abscessus lung disease: 'trouble ahead, trouble behind…'.

Griffith DE.

F1000Prime Rep. 2014 Nov 4;6:107. doi: 10.12703/P6-107. eCollection 2014. Review.

39.

Therapy for Mycobacterium avium complex lung disease. It ain't perfect, but it's progress.

Bag R, Griffith DE.

Am J Respir Crit Care Med. 2015 Jan 1;191(1):14-6. doi: 10.1164/rccm.201411-2078ED. No abstract available.

PMID:
25551346
40.

Variable agreement among experts regarding Mycobacterium avium complex lung disease.

Marras TK, Prevots DR, Jamieson FB, Winthrop KL; Pulmonary MAC Outcomes Group.

Respirology. 2015 Feb;20(2):348-51. doi: 10.1111/resp.12440. Epub 2014 Nov 28.

41.

The significance of Mycobacterium abscessus subspecies abscessus isolation during Mycobacterium avium complex lung disease therapy.

Griffith DE, Philley JV, Brown-Elliott BA, Benwill JL, Shepherd S, York D, Wallace RJ Jr.

Chest. 2015 May;147(5):1369-1375. doi: 10.1378/chest.14-1297.

42.

Reply: Latent tuberculosis infection among foreign-born persons: a prioritized approach.

Griffith DE.

Ann Am Thorac Soc. 2014 Oct;11(8):1336. doi: 10.1513/AnnalsATS.201408-382LE. No abstract available.

PMID:
25343204
43.

Eliminating tuberculosis one neighborhood at a time.

Cegielski JP, Griffith DE, McGaha PK, Wolfgang M, Robinson CB, Clark PA, Hassell WL, Robison VA, Walker KP Jr, Wallace C.

Am J Public Health. 2014 Apr;104 Suppl 2:S214-33. doi: 10.2105/AJPH.2012.300781r.

44.

Testing for latent tuberculosis. Applying the best of intentions.

Griffith DE.

Ann Am Thorac Soc. 2014 May;11(4):594-5. doi: 10.1513/AnnalsATS.201403-130ED. No abstract available.

PMID:
24828801
45.

Clinical experience in 52 patients with tigecycline-containing regimens for salvage treatment of Mycobacterium abscessus and Mycobacterium chelonae infections.

Wallace RJ Jr, Dukart G, Brown-Elliott BA, Griffith DE, Scerpella EG, Marshall B.

J Antimicrob Chemother. 2014 Jul;69(7):1945-53. doi: 10.1093/jac/dku062. Epub 2014 Mar 14.

46.

Nontuberculous mycobacterial (NTM) lung disease: the top ten essentials.

Aksamit TR, Philley JV, Griffith DE.

Respir Med. 2014 Mar;108(3):417-25. doi: 10.1016/j.rmed.2013.09.014. Epub 2013 Sep 25. Review.

47.

Macrolide/Azalide therapy for nodular/bronchiectatic mycobacterium avium complex lung disease.

Wallace RJ Jr, Brown-Elliott BA, McNulty S, Philley JV, Killingley J, Wilson RW, York DS, Shepherd S, Griffith DE.

Chest. 2014 Aug;146(2):276-282. doi: 10.1378/chest.13-2538.

48.

[Eliminating tuberculosis one neighborhood at a time].

Cegielski JP, Griffith DE, McGaha PK, Wolfgang M, Robinson CB, Clark PA, Hassell WL, Robison VA, Walker KP, Wallace C.

Rev Panam Salud Publica. 2013 Oct;34(4):284-94. Spanish.

PMID:
24301742
49.

In vitro activity of amikacin against isolates of Mycobacterium avium complex with proposed MIC breakpoints and finding of a 16S rRNA gene mutation in treated isolates.

Brown-Elliott BA, Iakhiaeva E, Griffith DE, Woods GL, Stout JE, Wolfe CR, Turenne CY, Wallace RJ Jr.

J Clin Microbiol. 2013 Oct;51(10):3389-94. doi: 10.1128/JCM.01612-13. Epub 2013 Aug 14. Erratum in: J Clin Microbiol. 2014 Apr;52(4):1311.

50.

First do no harm--adverse events, drug intolerance, and hepatotoxicity: how can we not justify directly observed therapy for treating tuberculosis?

Seaworth BJ, Armitige LY, Griffith DE.

Clin Infect Dis. 2013 Oct;57(7):1063-4. doi: 10.1093/cid/cit432. Epub 2013 Jun 27. No abstract available.

PMID:
23811418

Supplemental Content

Loading ...
Support Center